ES2071312T3 - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
ES2071312T3
ES2071312T3 ES91909572T ES91909572T ES2071312T3 ES 2071312 T3 ES2071312 T3 ES 2071312T3 ES 91909572 T ES91909572 T ES 91909572T ES 91909572 T ES91909572 T ES 91909572T ES 2071312 T3 ES2071312 T3 ES 2071312T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
core
prostaglandin
coating
nsaid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91909572T
Other languages
English (en)
Inventor
Rene Antoine Gimet
Jean-Charles Jinot
Christian Magnet
Isabelle Maroteaux
Francoise M Nevoux
Roger Scoyer
Barbara J Struthers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24063571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2071312(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2071312T3 publication Critical patent/ES2071312T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA QUE INCLUYE UN NUCLEO (18) DE UN NSAID SELECCIONADO A PARTIR DEL DICLOFENAC Y DEL PIROXICAM, NUCLEO QUE ESTA RODEADO POR UN REVESTIMIENTO DE MANTO (22) DE UNA PROSTAGLANDINA, EN DONDE PUEDE ESTAR PRESENTE UN REVESTIMIENTO INTERMEDIO (20) ENTRE EL NUCLEO DE NSAID Y EL REVESTIMIENTO DE MANTO DE PROSTAGLANDINA.
ES91909572T 1990-05-03 1991-05-01 Composicion farmaceutica. Expired - Lifetime ES2071312T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51835390A 1990-05-03 1990-05-03

Publications (1)

Publication Number Publication Date
ES2071312T3 true ES2071312T3 (es) 1995-06-16

Family

ID=24063571

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91909572T Expired - Lifetime ES2071312T3 (es) 1990-05-03 1991-05-01 Composicion farmaceutica.

Country Status (15)

Country Link
US (2) US5601843A (es)
EP (1) EP0527887B1 (es)
AT (1) ATE121625T1 (es)
AU (1) AU7876491A (es)
CA (1) CA2082944C (es)
DE (1) DE69109286T2 (es)
DK (1) DK0527887T3 (es)
ES (1) ES2071312T3 (es)
GR (1) GR3015939T3 (es)
IE (1) IE68596B1 (es)
IL (1) IL98033A (es)
NZ (1) NZ238024A (es)
PT (1) PT97562B (es)
WO (1) WO1991016895A1 (es)
ZA (1) ZA913353B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE121625T1 (de) * 1990-05-03 1995-05-15 Searle & Co Pharmazeutische zusammensetzung.
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
US5324746A (en) * 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
DE4341442C2 (de) * 1993-12-04 1998-11-05 Lohmann Therapie Syst Lts Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung
EP0853481A1 (en) * 1995-09-27 1998-07-22 Merck Frosst Canada Inc. Compositions for treating inflammation containing certain prostaglandins and a selective cyclooxygenase-2 inhibitor
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
AU742787B2 (en) 1997-07-09 2002-01-10 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
CA2241342C (en) * 1998-06-15 2000-02-08 Bernard Charles Sherman Pharmaceutical tablets comprising an nsaid and a prostaglandin
GB9814215D0 (en) * 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6319519B2 (en) 1998-07-07 2001-11-20 Norton Healthcare Ltd. Anti-inflammatory pharmaceutical formulations
US6514525B2 (en) 1998-09-10 2003-02-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6387410B1 (en) 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
GB9819685D0 (en) * 1998-09-10 1998-11-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
US7429407B2 (en) * 1998-12-30 2008-09-30 Aeromatic Fielder Ag Process for coating small bodies, including tablets
CA2259727A1 (en) * 1999-01-18 2000-07-18 Bernard Charles Sherman A two-layer pharmaceutical tablet comprising an nsaid and misoprostol
US6183779B1 (en) 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
CA2277407A1 (en) 1999-07-14 2001-01-14 Bernard Charles Sherman Pharmaceutical tablet comprising an nsaid and misoprostol
KR20020063871A (ko) * 1999-10-01 2002-08-05 노턴 헬스케어 리미티드 항 - 염증성 약학적 제제형
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
DE602004007315D1 (de) * 2003-03-03 2007-08-16 Personnes A Responsibilite Lim Stabilisierte pharmazeutische Zusammensetzung enthaltend einen NSAID und einen Prostaglandin
WO2004091579A1 (en) * 2003-04-16 2004-10-28 Pharmacia Corporation Stabilized prostaglandin formulation
US7241746B2 (en) 2003-08-06 2007-07-10 Regena Therapeutics, Lc Method and composition for treating periodontal disease
US20050163847A1 (en) * 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
US20060073202A1 (en) * 2004-10-05 2006-04-06 Rocca Jose G Dual component medicament delivery system
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20150224056A1 (en) * 2006-07-18 2015-08-13 Horizon Pharma Usa, Inc. Pharmaceutical compositions of ibuprofen and famotidine
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008027963A2 (en) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
EP2167048B1 (en) 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
EP2210595A1 (en) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
AU2017249011A1 (en) * 2016-04-11 2018-10-25 University Of Utah Research Foundation Methods for treating NSAID-induced cardiovascular, cerebrovascular, or renovascular adverse events

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135881A (en) * 1983-03-02 1984-09-12 Erba Farmitalia Method and pharmaceutical compositions for inhibiting or reducing gastrointestinal side effects of non-steroidal anti-inflammatory drugs
IT1190400B (it) * 1985-10-04 1988-02-16 Istituto Biochimico Italiano Derivati dell'acido 19,20-bis,nor-prostanoico ad attivita' antiulcera e anoressivca,procedimento per la loro preparazione e composizioni farmaceutiche
US4707495A (en) * 1985-10-28 1987-11-17 Ortho Pharmaceutical Peptic ulcer treatment method
US4975283A (en) * 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
DE3603576A1 (de) * 1986-02-06 1987-08-13 Code Kaffee Handel Verwendung von gerbstoffen und/oder chlorogensaeure sowie nahrungs-, genuss- und/oder arzneimittel mit gerbstoff- und/oder chlorogensaeurezusatz
JPH01139528A (ja) * 1987-11-24 1989-06-01 Showa Denko Kk 抗潰瘍剤
ATE121625T1 (de) * 1990-05-03 1995-05-15 Searle & Co Pharmazeutische zusammensetzung.

Also Published As

Publication number Publication date
IE911486A1 (en) 1991-11-06
PT97562A (pt) 1992-02-28
IL98033A (en) 1995-07-31
DK0527887T3 (da) 1995-07-03
ZA913353B (en) 1993-04-28
EP0527887B1 (en) 1995-04-26
CA2082944C (en) 1998-11-24
DE69109286T2 (de) 1995-09-28
EP0527887A1 (en) 1993-02-24
NZ238024A (en) 1993-08-26
GR3015939T3 (en) 1995-07-31
US5601843A (en) 1997-02-11
PT97562B (pt) 1998-08-31
IE68596B1 (en) 1996-06-26
WO1991016895A1 (en) 1991-11-14
DE69109286D1 (de) 1995-06-01
US5698225A (en) 1997-12-16
ATE121625T1 (de) 1995-05-15
CA2082944A1 (en) 1991-11-04
IL98033A0 (en) 1992-06-21
AU7876491A (en) 1991-11-27

Similar Documents

Publication Publication Date Title
ES2071312T3 (es) Composicion farmaceutica.
NO923947L (no) Smaksmaskering av ibuprofen ved fluidlagbelegning
DE69021635D1 (de) Beschichtete optische Übertragungsmedien.
DE69010594D1 (de) Optische Verstärker.
DE69104573D1 (de) Optischer Verstärker.
NO307813B1 (no) Farmasøytisk og galenisk preparatform
FR2670865B1 (fr) Lampe pour salle d'operation.
DE69114603T2 (de) Regulierventil.
DE59104119D1 (de) Membranventil.
DE69200867T2 (de) Betätigungseinrichtung eines Getriebes.
DE69104829T2 (de) Herstellung von reibbelägen.
DE3864108D1 (de) Steuerung der ausgangsleistung eines klasse-c-verstaerkers.
BR9606955A (pt) Heterocicloalquenos substituísos
PT840735E (pt) Resolucao de 2-(difenilmetil)-n-{¬2-metoxi-5-(1-metiletil)fenil|metil}-1-azabiciclo¬2.2.2|octan-3-amina
DE69107563T2 (de) Friktionstellantrieb.
FI900273A0 (fi) Anordning foer utfaellning av fibermassa.
SU1829367A1 (ru) 5-(1-гидрокси-1-метоксикарбонил-2,2,2-трифторэтил)-8-трибутилоловооксихинолин, проявляющий антистафилококковую активность
DK316188D0 (da) Sulfolipopolysaccharider som stimolatorer for den ikke specifikke forsvarsmekanisme
DE59105276D1 (de) Optischer verstärker.
FR2690766B1 (fr) Interface programmable notamment pour la commande d'installations domestiques.
RU1825905C (ru) Кольцева пружина Н.Н.Рахманова
RU1768078C (ru) Регул тор оросительного трубопровода
FR2664353B1 (fr) Clapet pour pulverisateur.
FR2663664B1 (fr) Batiment, notamment pour l'aviculture.
YU47111B (sh) Jedinjenje hroma i postupak za izradu hromnih jedinjenja

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 527887

Country of ref document: ES